Clinical Trials
1.1k
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (719 trials with phase data)• Click on a phase to view related trials
Asian Gynecological Brachytherapy Registry in Cervical Cancer
- Conditions
- Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Stage IVA Cervical Cancer FIGO 2018Stage IB Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT07196033
- Locations
- 🇮🇳
Tata Memorial Center, Mumbai, Maharashtra, India
🇯🇵Gunma University, Maebashi, Japan, Japan
🇯🇵Juntendo University, Tokyo, Japan, Japan
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
- Conditions
- Neuroendocrine Neoplasia's (NENs)Neuroendocrine Tumor GEP Grade 1-3Neuroendocrine Gastroenteropancreatic Tumour
- Interventions
- Radiation: Peptide Receptor Radionuclide Therapy with Lu177 DOTATATEDrug: Capecitabine plus temozolamide
- First Posted Date
- 2025-09-22
- Last Posted Date
- 2025-09-22
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 162
- Registration Number
- NCT07185672
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, India, Mumbai, Maharashtra, India
🇮🇳Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Navi Mumbai, Maharashtra, India
Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.
- Conditions
- Vulvo-vaginal Cancer
- First Posted Date
- 2025-09-18
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT07179757
- Locations
- 🇮🇳
Tata Memorial Hospital, Mumbai, Maharashtra, India
A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.
- Conditions
- Uterine Cervical Neoplasm
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 316
- Registration Number
- NCT07164534
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
- Conditions
- Cervical Carcinoma
- First Posted Date
- 2025-02-03
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Tata Memorial Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT06804135
- Prev
- 1
- 2
- 3
- 4
- 5
- 19
- Next
News
Phase III BART Trial Shows Adjuvant Radiation Therapy Significantly Reduces Pelvic Recurrence in High-Risk Bladder Cancer
The BART trial demonstrated that post-operative radiation therapy reduced locoregional recurrence rates from 26% to 8% in patients with high-risk muscle-invasive bladder cancer.
India's Indigenous CAR T-Cell Therapy Revolutionizes Cancer Treatment at One-Tenth Global Cost
India has successfully developed NexCAR19, its first indigenous CAR T-cell therapy for blood cancers, priced at approximately Rs 40 lakh ($50,000) compared to $400,000 in the United States.